Thursday, March 7, 2013
This week in therapeutics
Publication and contact
Acute lung injury
IL-6; IL-6 receptor (IL-6R;
CD126); IL-6 signal transducer
(IL-6ST; gp130; CD130)
Human plasma and mouse
studies suggest inhibiting IL-6 trans-signaling could help treat pancreatitis-associated
acute lung injury. In patients with acute pancreatitis who progressed to lung
or other organ failure, plasma taken at disease onset showed significantly
higher IL-6 and IL-6R levels than plasma from individuals with mild acute
pancreatitis (p<0.001). In a mouse model for acute pancreatitis-induced
lethal acute lung injury, a fusion protein called sgp130Fc
that inhibits IL-6 trans-signaling decreased lung injury and increased
survival compared with no treatment. Next steps include testing sgp130Fc or
the anti-IL-6 mAb Actemra tocilizumab in
patients with acute pancreatitis-associated acute lung injury and as a
prophylactic in patients undergoing pancreatic endoscopy, which increases the
risk of pancreatitis.
Roche and partner Chugai Pharmaceutical Co. Ltd.
have Actemra in Phase III testing to treat ankylosing spondylitis and Phase
II testing to treat scleroderma.
Regeneron Pharmaceuticals Inc.
and partner Sanofi have sarilumab,
an anti-IL-6R human mAb, in Phase III testing to treat rheumatoid arthritis
Ablynx N.V.'s ALX-0061, an anti-IL-6R
nanobody, is in Phase II testing to treat RA.
Published online March 7, 2013
Sgp130Fc patented; licensed
to the Conaris Research Institute AG;
protein out-licensed to Ferring Pharmaceuticals A/S
for use in inflammatory bowel disease (IBD)
Zhang, H. et al. J.
Clin. Invest.; published online Feb. 15, 2013;
Contact: Hana Algül, Technical University Munich, Munich, Germany
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]